Safety and Efficacy of AK0529 in Respiratory Syncytial Virus-Infected Infant Patients: a Phase 2 Proof-of-Concept Trial

Li-Ming Huang1, Andreas Schibler2, Yi-Chuan Huang3, Andrew Tai4, Hsin Chi5, Chae-Hee Chieng6, Jinn-Li Wang7, Aviv Goldbart8, Swee-Ping Tang9, YC Huang10, Shane George11, Derya Alabaz12, Siew-Choo Su13, Jessie de Bruyne14, Bulent Karadag15, Lea Bentur16, Feng Gu17, Gang Zou17, Stephen Toovey17, John Devincenzo18, and Jim Wu17

1National Taiwan University College of Medicine
2Wesley Medical Research Ltd
3Chang Gung Memorial Hospital Kaohsiung Branch
4Women’s and Children’s Hospital Adelaide
5Mackay Memorial Hospital
6Sibu Hospital
7Taipei Municipal Wan-Fang Hospital
8Soroka Medical Center
9Hospital Selayang
10Chang Gung Memorial Hospital Linkou Main Branch
11Gold Coast University Hospital
12Cukurova University Faculty of Medicine
13Tengku Ampuan Rahimah Hospital
14University of Malaya Medical Centre
15Marmara University
16Ruth Rappaport Children’s Hospital
17Ark Biopharmaceutical
18Le Bonheur Children’s Medical Center

October 17, 2022

Abstract

Background. Respiratory syncytial virus (RSV) infection is a cause of substantial morbidity and mortality in young children. There is currently no effective therapy available. Methods. This was a phase 2 study of the oral RSV fusion protein inhibitor AK0529 in infants aged 1-24 months, hospitalized with RSV infection. In part 1 patients (n=24) were randomized 2:1 to receive a single dose of AK0529 up to 4 mg/kg or placebo. In part 2 patients (n=48) were randomized 2:1 to receive AK0529 at 0.5, 1 or 2 mg/kg bid or placebo for five days. Sparse pharmacokinetic samples were assessed using population pharmacokinetics modelling. Safety, tolerability, viral load, signs and symptoms were assessed daily during treatment. Results. No safety or tolerability signals were detected for AK0529: grade ≥3 treatment-emergent adverse events occurred in 4.1% of patients in AK0529 and 4.2% in placebo groups, respectively, and none led to death or withdrawal from the study. In part 2, targeted drug exposure was reached with 2 mg/kg bid. A numerically greater reduction in median viral load with 2 mg/kg bid AK0529 than with placebo at 96 hours was observed. A -4.0 (95% CI: -4.51, -2.03) median reduction in RSV signs and symptom score from baseline to 96 hours was observed in the 2 mg/kg group, compared with -2.0 (95% CI: -3.42, -1.82) in the placebo group. Conclusions. AK0529 was well tolerated in hospitalized RSV-infected infants. Treatment with AK0529 2 mg/kg bid
was observed to reduce viral load and clinical signs and symptoms.

Hosted file